Litcius/Paper detail

Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial

Mario Campone, Michelino De Laurentiis, Claudio Zamagni, Igor Kudryavcev, Mariëtte J Agterof, Ursa Brown‐Glaberman, Markéta Palácová, Sanjoy Chatterjee, Lakshmi Menon-Singh, Jiwen Wu, Miguel Martín

2022Breast Cancer Research and Treatment16 citationsDOI

Topics & Concepts

MedicineLetrozoleTolerabilityInternal medicineNeutropeniaPopulationBreast cancerClinical endpointMetastatic breast cancerOncologyAdverse effectDiscontinuationCancerSurgeryClinical trialChemotherapyTamoxifenEnvironmental healthAdvanced Breast Cancer TherapiesEstrogen and related hormone effectsProstate Cancer Treatment and Research
Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial | Litcius